Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA; Department of Dermatology, Mayo Clinic, Rochester, MN, 55905, USA.
Hum Pathol. 2024 Aug;150:1-8. doi: 10.1016/j.humpath.2024.06.006. Epub 2024 Jun 12.
Sweat gland neoplasms represent a challenging area of dermatopathology, as they are relatively uncommon and often histopathologically complex. Recent studies have uncovered distinct immunohistochemical and molecular profiles in several sweat gland neoplasms, including digital papillary adenocarcinoma (DPA), papillary eccrine adenoma/tubular apocrine adenoma (PEA/TAA), poroid family tumors (PFT)/porocarcinoma, and clear cell hidradenoma (CCH)/clear cell hidradenocarcinoma (CCHCa). To further evaluate the diagnostic utility of ancillary studies in various sweat gland neoplasms, we performed an independent validation study in a cohort of patients with acral and non-acral tumors (9 DPA, 8 PEA/TAA, 13 PFT, 5 porocarcinoma, 23 CCH, 7 CCHCa, 6 sweat gland carcinoma not otherwise specified). p63 immunohistochemistry (IHC) demonstrated a myoepithelial pattern in 8/8 DPA and 4 of 4 tested PEA/TAA cases, and showed a ductal pattern in all tested PFT/porocarcinoma and CCH/CCHCa cases (42/42). All PEA/TAA (8/8) cases were positive for BRAF V600E IHC. 5 of 12 tested PFT and 5/5 porocarcinoma cases showed either positive staining with NUT IHC or harbored YAP1::NUTM1 fusion gene by RNA sequencing. MAML2 fluorescence in situ hybridization (FISH) was positive in all CCH and CCHCa cases (23/23 and 7/7, respectively). Our results further support the usefulness of appropriate ancillary studies in precise classification of sweat gland tumors, which may be routinely applied in diagnostic pathology practice when morphologic evaluation is in doubt.
汗腺肿瘤是皮肤科病理学中的一个具有挑战性的领域,因为它们相对罕见,且通常组织病理学表现复杂。最近的研究揭示了几种汗腺肿瘤(包括指状乳头状腺癌[DPA]、乳头状汗管腺瘤/管状大汗腺腺瘤[PEA/TAA]、多孔家族肿瘤[PFT]/汗孔癌、透明细胞汗腺瘤[CCH]/透明细胞汗腺癌[CCHCa])中独特的免疫组织化学和分子特征。为了进一步评估辅助研究在各种汗腺肿瘤中的诊断效用,我们在一组肢端和非肢端肿瘤患者中进行了一项独立的验证研究(9 例 DPA、8 例 PEA/TAA、13 例 PFT、5 例汗孔癌、23 例 CCH、7 例 CCHCa、6 例未特指的汗腺癌)。p63 免疫组织化学(IHC)在 8/8 例 DPA 和 4/4 例测试的 PEA/TAA 病例中显示出肌上皮模式,并且在所有测试的 PFT/汗孔癌和 CCH/CCHCa 病例中显示出导管模式(42/42)。所有 PEA/TAA(8/8)病例的 BRAF V600E IHC 均为阳性。12 例 PFT 中有 5 例和 5/5 例汗孔癌中有 5 例显示 NUT IHC 阳性染色,或通过 RNA 测序显示 YAP1::NUTM1 融合基因。MAML2 荧光原位杂交(FISH)在所有 CCH 和 CCHCa 病例中均为阳性(分别为 23/23 和 7/7)。我们的结果进一步支持了适当的辅助研究在汗腺肿瘤的精确分类中的有用性,当形态学评估存在疑问时,这些研究可能会在诊断病理学实践中常规应用。